News Releases

Date Title and Summary Additional Formats
Toggle Summary Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2019 Financial Results
SAN DIEGO , March 04, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel anti-infectives, reported financial results for the three months and full year ended December 31, 2019
View HTML
Toggle Summary Cidara Therapeutics to Present at Transplantation & Cellular Therapy (TCT) and Mycology 2020 Medical Conferences
SAN DIEGO , Feb. 18, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing therapeutics to improve the standard of care for patients facing severe fungal or viral infections, today announced that it will present a poster at the Transplantation &
View HTML
Toggle Summary Cidara Therapeutics Announces Closing of Rights Offering
SAN DIEGO , Feb. 12, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (“Cidara”) today announced the closing of its previously announced rights offering (the “Rights Offering”). At the closing, Cidara sold and issued an aggregate of 6,639,307 shares of its common stock (the “Common
View HTML
Toggle Summary Cidara Therapeutics Announces Commencement of Rights Offering
SAN DIEGO , Jan. 22, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (“Cidara”) today commenced the previously announced rights offering to raise gross proceeds of approximately $30.0 million (the “Rights Offering”). Under the terms of the Rights Offering, the holders, as of 5:00
View HTML
Toggle Summary Cidara Therapeutics Announces Proposed Rights Offering
Rights Offering will be available to all stockholders and 2018 warrant holders of record on January 21, 2020 $30.0 million to be raised, fully backstopped SAN DIEGO , Jan. 10, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (“Cidara”) today announced its intent to raise $30.0
View HTML